These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36624250)

  • 1. Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies.
    Kumar SS; Bagepally BS; Sasidharan A
    Clin Drug Investig; 2023 Feb; 43(2):97-108. PubMed ID: 36624250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic interventions for fatigue in rheumatoid arthritis.
    Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
    Kielhorn A; Porter D; Diamantopoulos A; Lewis G
    Curr Med Res Opin; 2008 Sep; 24(9):2639-50. PubMed ID: 18687164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies.
    Kumar SS; Haridoss M; Venkataraman K; Bagepally BS
    Front Pharmacol; 2022; 13():1090361. PubMed ID: 36582538
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china.
    Wu B; Wilson A; Wang FF; Wang SL; Wallace DJ; Weisman MH; Lu LJ
    PLoS One; 2012; 7(10):e47373. PubMed ID: 23056637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.
    Ahmadiani S; Nikfar S; Karimi S; Jamshidi AR; Akbari-Sari A; Kebriaeezadeh A
    Rheumatol Int; 2016 Sep; 36(9):1291-300. PubMed ID: 27136919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA; Cameron DR
    J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.